Research programme: bone disorder therapeutics - Enzo Therapeutics/University of Conneticut

Drug Profile

Research programme: bone disorder therapeutics - Enzo Therapeutics/University of Conneticut

Alternative Names: Enzo D58; IIIC3

Latest Information Update: 30 Sep 2009

Price : $50

At a glance

  • Originator Enzo Therapeutics; University of Connecticut
  • Class Small molecules
  • Mechanism of Action Osteogenesis stimulants; Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bone disorders; Periodontal disorders

Most Recent Events

  • 30 Sep 2009 Discontinued - Preclinical for Bone disorders in USA (unspecified route)
  • 30 Sep 2009 Discontinued - Preclinical for Periodontal disorders in USA (unspecified route)
  • 10 Oct 2005 A preclinical study has been added to the Musculoskeletal Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top